Lamotrigine as Add-On Therapy in Schizophrenia: Results of 2 Placebo-Controlled Trials
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: : Lamotrigine previously was found to attenuate ketamine-induced behavioral changes and, in 2 placebo-controlled trials, to improve psychosis when added to antipsychotic medication. We sought to evaluate the potential role of lamotrigine augmentation in schizophrenia patients resistant to atypical antipsychotic medication. METHODS: : Two multicenter, randomized, double-blind, 12-week, parallel-group trials were conducted to compare flexibly dosed lamotrigine (100-400 mg/d) with placebo as add-on treatment in schizophrenia patients with stable, residual psychotic symptoms. The primary end point was changed in Positive and Negative Syndrome Scale total score at week 12. RESULTS: : Two hundred seventeen patients were enrolled in study 1 and 212 in study 2; completion rates in the intent-to-treat samples were 71% and 74%, respectively, and did not differ between treatment groups. Overall, mean Positive and Negative Syndrome Scale total scores improved in both studies and did not differ between treatment groups. In study 1, the Scale for Assessment of Negative Symptoms total score and Clinical Global Impression improved more with placebo than with lamotrigine; in study 2, the cognitive composite score improved more with lamotrigine than with placebo. CONCLUSIONS: : Results from these 2 studies do not support the use of lamotrigine as an adjunct to atypical antipsychotics in patients with refractory psychosis. It is unclear why positive results from previous lamotrigine trials were not replicated. The positive effect of lamotrigine on cognition in one trial, while of uncertain significance, may merit further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“Ketamine is believed to produce symptoms of schizophrenia by preferentially blocking NMDA receptors on a subset of GABAergic inhibitory interneurons,(5,6) resulting in excessive glutamate release acting at nonNMDA glutamate receptors.(7,8) N-methyl-D-aspartate antagonism additionally disrupts firing patterns in princi…”
BackgroundNMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426 · cited 1×
“It is hypothesized that lamotrigine inhibits excessive glutamate release and aberrant neuronal activity associated with reduced inhibitory feedback.(13,14) Similarly, the metabotropic glutamate type II receptor agonist, LY354740, was found to decrease glutamate release and attenuate behavioral effects of phencyclidine…”
BackgroundSelf-citationKrystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1982-8 · Cited by 272
Self-citationInternal and external validity of the WHO Well‐Being Scale in the elderly general population
Heun, R., Burkart, M., Maier, W., & Bech, P. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb00973.x · Cited by 160 · cited 2×
“Secondary efficacy assessments included positive and general psychopathology symptoms assessed with the PANSS subscale scores, negative symptoms assessed with the Scale for Assessment of Negative Symptoms (SANS),25 and illness severity measured with the CGI-Severity (CGI-S) scale.26 Study 1 assessed QOL using the chan…”
MethodThe potential role of lamotrigine in schizophrenia
Large, C. H., Webster, E. L., & Goff, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0020-9 · Cited by 69
Self-citation
Cited by
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Wang, M., Yang, Y., Wang, C.-J., Gamo, N. J., Jin, L. E., Mazer, J. A., Morrison, J. H., Wang, X.-J., & Arnsten, A. F. T. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.032 · Cited by 489
“The data also explain why treatments that reduce NMDAR actions, based on the hyperglutamate theory of schizophrenia, have failed or even worsened symptoms (Goff et al., 2007; Lieberman et al., 2009).”
BackgroundBarnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Moghaddam, B., & Krystal, J. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs075 · Cited by 238
Self-citation
Metadata
- Authors
- Goff, D. C., Keefe, R., Citrome, L., Davy, K., Krystal, J. H., Large, C., Thompson, T. R., Volavka, J., & Webster, E. L.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-12
- Volume
- 27
- Issue
- 6
- Pages
- 582-589
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2037457244
- Cited by
- 120
- References
- 8
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lamotrigine as Add-On Therapy in Schizophrenia: Results of 2 Placebo-Controlled Trials. https://app.cochat.ai/papers/10.1097/jcp.0b013e31815abf34
- The paper
- Goff, D. C., Keefe, R., Citrome, L., Davy, K., Krystal, J. H., Large, C., Thompson, T. R., Volavka, J., & Webster, E. L. (2007). Lamotrigine as Add-On Therapy in Schizophrenia: Results of 2 Placebo-Controlled Trials. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31815abf34
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.